Background: The International Thymic Malignancy Interest Group (ITMIG) proposed an internationally accepted division of the mediastinum into three compartments based on computed tomography (CT): anterior (prevascular), middle (visceral) and posterior (paravertebral) compartment. There is no generally accepted definition for the term “giant” when applied to middle mediastinal lesions. We defined the term “giant” and described our surgical experience in treating patients with giant lesions of the middle mediastinum. Methods: CT imaging of patients operated in our center from January 2016 to August 2021 for mediastinal lesions was reviewed. Lesions were categorized to one of the ITMIG-defined compartments. Lesion size at diagnosis was measured at its largest diameter on axial CT imaging. Giant middle mediastinal lesions were defined as lesions having a size ≥90th percentile of our middle mediastinal lesion cohort. Patients with giant middle mediastinal lesions were further analyzed. Results: Thirty-six patients (23%) had lesions located in the middle mediastinal compartment. Most common diagnoses were mediastinal cysts (n=10, 28%), metastatic lesions (n=6, 17%), lymphomas (n=5, 14%), and sarcomas (n=3, 8%). Ninetieth percentile lesion size was 73 mm. As per definition, four patients had giant middle mediastinal lesions. All these four lesions were of mesenchymal origin including oesophageal leiomyoma, synovial sarcoma, leiomyosarcoma and undifferentiated round cell sarcoma. Resection was performed through posterolateral thoracotomy or sternotomy, with or without cardiopulmonary bypass. Conclusions: The term “giant” could be defined as a mass larger or equal to 73 mm. This definition selected specifically lesions with mesenchymal origin and may therefore guide diagnostic algorithm and patient management.
Objective: Ewing sarcoma (EWS) of the mediastinum is extremely rare, with only a few cases reported in the literature. We aimed to gain a better understanding of primary mediastinal EWS, describing patients treated within two international, multicenter, prospective, randomized EWS trials. Methods: Data from patients with primary mediastinal EWS were retrieved from the database of the EURO-E.W.I.N.G.99 (ClinicalTrials.gov identifier: NCT00020566) and EWING 2008 (ClinicalTrials.gov identifier: NCT00987636) trials. Patient and treatment characteristics were analyzed. Results: Out of 2969 patients with EWS, 9 (0.3%) had primary mediastinal EWS. The median age at diagnosis was 30.5 years (4 to 49). At the time of diagnosis, n = 3 (33%) patients had synchronous metastases. All patients underwent multiagent chemotherapy. Local therapy for non-metastatic patients was surgery (n = 2, 22%), surgery and radiotherapy (n = 2, 22%) or radiotherapy alone (n = 2, 22%). Surgery consisted of extended resections in most patients (n = 3, 33%). Five-year survival for the whole cohort was 64%. Apart from one patient who was lost to follow-up, all patients (n = 4) who had undergone surgery were alive at the end of follow-up. Conclusions: Primary mediastinal ES is extremely rare, with a prevalence of 0.3% among EWS. Five-year survival was favorable compared to primary mediastinal sarcoma of all histologies and in line with EWS of different origin.
15 August 2025 in Langenbeck's Archives of Surgery
Purpose: Segmentectomy has become the new standard of care for selected patients with stage IA1-2 non-small cell lung cancer (NSCLC). For stage IA3 NSCLC, lobectomy is indicated. This study aims to compare the outcome after segmentectomy and lobectomy in patients with stage IA3 NSCLC. Methods: We retrospectively reviewed all patients undergoing surgery for NSCLC in our center between 2013 and 2023. We identified all patients who underwent segmentectomy or lobectomy for pathological stage IA3 tumors. Survival was calculated from the date of surgery until last follow- up. Univariate analysis was performed to study the impact on overall survival (OS) and disease-free survival (DFS) of clinical variables. Results: We identified fifty-nine patients undergoing surgery for stage IA3 NSCLC. Twenty- seven (28%) patients underwent segmentectomy and sixty-eight (72%) patients underwent lobectomy. Median age was 68 years (47–85). Median FEV1 was 74% (39–140), median DLCO was 67% (28–128). Surgery was performed by VATS in most cases (91%). There was no difference in age and lung function between the lobectomy and segmentectomy groups. Five-year OS was 67%. 5-year DFS was 63%. Five-year DFS was significantly worse in patients who underwent segmentectomy compared to lobectomy (37% vs. 72%, p = 0.040). There was no difference in 5-year OS (56% vs. 69%, p = 0.56). Conclusion: Segmentectomy is associated with significantly worse disease-free survival compared to lobectomy in our cohort of patients with stage IA3 NSCLC.
4 June 2025 in Journal of Cardiothoracic and Vascular Anesthesia
To evaluate the effect of prophylactic intravenous tranexamic acid (TXA) on bleeding complications, thromboembolic events, and hospital stay in patients undergoing thoracic surgery. Retrospective matched-pair analysis of registry data. German Thorax Registry data from multiple thoracic surgery centers across Germany. A total of 1,034 adult patients undergoing thoracic surgical procedures, matched 1:1 (517 received intravenous TXA, 517 did not). Administration of prophylactic intravenous TXA prior to thoracic surgery. Postoperative bleeding complications, including reoperations for bleeding and transfusion requirements, did not differ significantly between groups. However, thromboembolic complications were significantly less frequent in the TXA group (1.0% v 5.1%). Cardiac complications were also less frequent in the TXA group. No significant differences were observed in overall complication rates or length of hospital stay. Prophylactic intravenous TXA did not reduce bleeding complications in thoracic surgery but was associated with a lower incidence of thromboembolic and cardiac events. While no definitive conclusions can be made about the efficacy of TXA in reducing bleeding complications, the study offers insights into its potential role in reducing thromboembolic and cardiac complications. A well-powered, randomized controlled trial is needed to confirm these results.
To evaluate outcome and prognostic factors of patients with primary pulmonary sarcoma (PPS) who underwent curative-intent surgery within multimodality treatment. An international, multicenter, retrospective study including patients with PPS was performed through a network of sarcoma experts. Data on demographics, staging, treatment, and outcomes were retrieved. Overall survival was calculated from the date of diagnosis. Prognostic factors were assessed using uni- and multivariate analysis. Eighteen centers from 9 countries contributed, for a total of 173 patients. One hundred fifteen patients (66%) underwent curative-intent surgery within multimodality treatment. There were 58 male patients (50%). Twenty-two patients (20%) had metastases, mainly to lung (n = 7, 30%) and pleura (n = 9, 39%). Thirty-three patients (30%) underwent preoperative chemotherapy. Extent of lung resection was sublobar (n = 11, 10%), lobar (n = 58, 54%), or bilobar/pneumonectomy (n = 39, 36%). Median tumor size was 85 mm. Sixty-nine patients had grade 3 tumors (71%). Resection was complete in 85 patients (75%). Lymphadenectomy was performed in 70 patients (63%), with nodal involvement in 10 (14%). Thirty-seven (37%) patients received adjuvant chemotherapy, and 27 (27%) patients received adjuvant radiotherapy. Overall survival was 49% and 31% at 5 and 10 years, respectively. Median follow-up was 33 months. Male gender (P = .003), age older than 60 years (P = .021), presence of metastasis (P = . 002), tumor size >40 mm (P = . 046), and incomplete resections (P = . 008) were independent prognostic factors for poor survival. In patients with curative-intent multimodal treatment for PPS, an encouraging 5-year survival rate of 49% can be achieved in expert centers. Independent prognostic factors may aid in selecting patients for curative treatment.
Background: Mediastinal tracheostomy (MT) is a rare, technically demanding salvage procedure in which the distal trachea is redirected into the upper mediastinum. It is indicated when extensive resection of the proximal trachea precludes conventional tracheal reconstruction or cervical tracheostomy. It is performed for a variety of underlying diseases. The aim of this systematic review was to summarize the available evidence on operative techniques, perioperative outcomes, disease-specific outcomes, and quality of life. Methods: A systematic review was conducted. PubMed was searched for case reports and case series. Data on surgical techniques, indications, perioperative outcomes, complications, and quality of life were descriptively analyzed. Results: Seventy publications reporting 437 mediastinal tracheostomies over 85 years were identified. Of these, 429 were permanent anterior mediastinal tracheostomies, the predominant type. Several techniques have evolved for this procedure over time. Extended manubrial resection was performed in most cases, whereas hemi-manubrial resection (2.8%) has gained popularity in recent years. Although a tracheal stump length of ≥5 cm is generally recommended, 12.6% of tracheostomies were created with a stump measuring 0–4 cm. Tracheal transposition was performed in 52.9% of cases to increase tracheal length and avoid contact with the brachiocephalic artery. Initially, direct collar skin (20.3%) or bipedicled upper thoracic skin flaps (13.8%) were used for reconstruction; more recently, the pectoralis major myocutaneous flap (32.9%) has become the predominant technique. Postoperative mortality was 7.0% and decreased over time. Major complications included great vessel rupture (6.8%), tracheal necrosis (8.4%), and tracheal stenosis (9.6%). Patients with a tracheal stump length of 0–3cm had a failure rate of 33.3%. Available data did not permit reliable conclusions on outcomes for specific malignancy types. Quality-of-life data were scarce, although individual reports described independent daily living and return to strenuous work for more than 10 years. Conclusions: Permanent anterior MT remains the standard form of MT and can provide acceptable outcomes when meticulous surgical technique is applied. Tracheal transposition and well-vascularized muscle flap reconstruction appear to reduce procedure-related complications, particularly in patients with short tracheal remnants. Prospective multicenter studies are needed to define optimal surgical strategies, long-term oncological outcomes, and patient-reported quality of life.